AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 132 min read$ZLAB

Chen Yajing sold $15K of ZLAB

Chen Yajing (Chief Financial Officer) sold 619 shares of Zai Lab Ltd (ZLAB) at $25.00 on 2026-08-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Chen Yajing
Published Aug 13, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 8:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ZLAB
Neutral
high confidence
Mentioned
$ZLAB
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ZLABNeutralLow
01

Why it matters

This disclosure updates the record of insider activity but does not include any new company fundamentals such as earnings, guidance, trials, contracts, or regulatory actions.

02

Market read

Traders may log the transaction for sentiment monitoring, but the pre-arranged nature makes it unlikely to drive a fundamental repricing.

03

What to watch

The article does not state whether the CFO has other concurrent grants, option exercises, or tax-related sales, which can explain sale volume without signaling fundamentals.

Relevance 2/10Novelty 3/10Timing: SEC Form 4 filed after-hours on 2026-08-13, reflecting the 2026-08-11 sale.

Background

The article is an SEC Form 4 insider transaction disclosure for Zai Lab Ltd, reported by the CFO.

Company-level read

Ticker impact

$ZLABNeutralHigh confidence
Context

Zai Lab CFO Chen Yajing sold 619 shares at $25.00 on 2026-08-11 under a pre-arranged 10b5-1 plan, per Form 4.

Expected impact

Likely negligible near-term price impact; any reaction should be muted given the pre-arranged 10b5-1 structure.

Evidence & confidence

The filing specifies an open-market sale and explicitly notes a pre-arranged Rule 10b5-1 plan, which typically dampens interpretive value versus non-10b5-1 sales.

Market effects

Sector

No sector read-through is provided; this is a single-company insider transaction with no operational or guidance change.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even with a 10b5-1 plan, repeated insider selling can coincide with internal caution; traders may still watch for follow-on sales or changes in buying behavior.

Key entities

  • issuer
    Zai Lab Ltd

    Subject of the Form 4 insider sale disclosure.

  • insider
    Chen Yajing

    Chief Financial Officer who executed the sale.

  • trading mechanism
    Rule 10b5-1 plan

    Pre-arranged plan cited as Yes, which typically reduces interpretive signal.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ZLAB insider trading history →

Related articles

OCT 23
$ZLABMedAI 8/10

Zai Lab’s Zoci Shows 82% Response Rate in Early Lung Cancer Study

Zai Lab's (ZLAB) experimental drug Zoci showed an 82% response rate in an early lung cancer study. The 1.6 mg/kg cohort had 81.9% six-month progression-free survival. Zoci with atezolizumab and carboplatin had a 92.3% response rate but increased toxicity. Zai Lab plans a global Phase III study by 2026, aiming to replace chemotherapy in frontline treatment. The company expects multiple program readouts and a potential U.S. biologics license application submission next year.

finance.yahoo.com2 min
OCT 23
$ZLABHighAI 9/10

Why is Zai Lab stock surging today?

Zai Lab (ZLAB) stock rose 7.2% to $23.62 after releasing Phase 1b trial data for its oncology drug zocilurtatug pelitecan, showing an 81.8% response rate. The company also announced a $250M capital raise from institutional investors. Analysts have an average price target above current levels.

investing.com2 min
OCT 23
$ZLABMedAI 8/10

Zai Lab's Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer

Zai Lab (ZLAB) reported positive Phase 1b trial results for zocilurtatug pelitecan (zoci) plus atezolizumab in extensive-stage small cell lung cancer (ES-SCLC). The combination achieved an 81.8% response rate and 81.9% 6-month progression-free survival rate. The therapy was well-tolerated, with Grade >3 adverse events in 9.1% of patients. Zai Lab plans to initiate a global Phase 3 trial by year-end 2026.

thailand-business-news.com3 min
OCT 23
$ZLABMedAI 9/10

Zai Lab Limited: Zai Lab's Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer

Zai Lab's (ZLAB) drug zocilurtatug pelitecan (zoci) showed 81.8% response rate and 81.9% 6-month progression-free survival in a Phase 1b trial for extensive-stage small cell lung cancer. The combination with atezolizumab was well-tolerated. A Phase 3 trial is planned for 2026. Zai Lab will discuss the data in an investor call.

finanznachrichten.de3 min
OCT 23
$ZLABHighAI 9/10

Zai Lab reports phase 1b trial data for lung cancer treatment

Zai Lab (ZLAB, 9688) reported Phase 1b trial data for zocilurtatug pelitecan with atezolizumab in lung cancer treatment. At 1.6 mg/kg, 81.8% response rate and 81.9% six-month progression-free survival were observed. Adverse events were mostly mild. A triplet regimen showed 92.3% response rate but higher severe adverse events. Zai Lab plans a Phase 3 study by year-end 2026.

investing.com2 min